Physician profile
Lauren K Junk
NPI 1861945131
$14,926.03
in general payments reported to CMS, 2019-2025
27 companies · $2,265 in 2025
The $2,265 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,105 · 2022: $2,265 · 2023: $7,266 · 2024: $2,025 · 2025: $2,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,832 · Consulting Fee: $2,550 · Travel and Lodging: $1,070 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,831.62 |
| Consulting Fee | $2,550.00 |
| Travel and Lodging | $1,069.90 |
| Education | $104.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $4,898.16 | 2022-2025 | Briumvi |
| Biogen, INC. | $1,871.69 | 2021-2025 | Tysabri, Vumerity, Plegridy |
| Genentech USA, INC. | $1,847.65 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $1,229.03 | 2021-2025 | |
| Genzyme Corporation | $1,136.25 | 2021-2025 | |
| Emd Serono, INC. | $1,084.21 | 2021-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $1,011.29 | 2021-2025 | Soliris, Ultomiris |
| Celgene Corporation | $525.37 | 2021-2025 | Zeposia |
| Mallinckrodt Hospital Products INC. | $154.54 | 2021-2024 | Acthar |
| Genentech, INC. | $153.42 | 2024-2025 | Ocrevus |
| Banner Life Sciences, LLC | $109.94 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $107.10 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $99.50 | 2022 | |
| Ani Pharmaceuticals, INC. | $83.38 | 2022-2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $74.98 | 2025 | Ponvory |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $73.54 | 2022-2024 | Glatiramer Acetate |
| Horizon Therapeutics Plc | $66.99 | 2022-2023 | Uplizna |
| Cycle Pharmaceuticals INC | $65.72 | 2024-2025 | Tascenso Odt, Bafiertam |
| Avanir Pharmaceuticals, INC. | $61.99 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $61.13 | 2023-2024 | Nuedexta |
| Acorda Therapeutics, INC | $52.21 | 2022-2024 | Ampyra |
| Axsome Therapeutics, INC. | $35.76 | 2023-2024 | Sunosi |
| Sandoz INC. | $34.18 | 2024 | |
| Almatica Pharma LLC | $30.57 | 2021 | |
| Amgen INC. | $28.91 | 2024-2025 | Uplizna |
| Sumitomo Pharma America, INC. | $15.62 | 2025 | Gemtesa |
| Abbvie INC. | $12.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Junk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.